Cargando…
Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non–small cell lung cancer: Analysis of over 8000 cases
BACKGROUND: Circulating cell‐free tumor DNA (ctDNA)‐based mutation profiling, if sufficiently sensitive and comprehensive, can efficiently identify genomic targets in advanced lung adenocarcinoma. Therefore, the authors investigated the accuracy and clinical utility of a commercially available digit...
Autores principales: | Mack, Philip C., Banks, Kimberly C., Espenschied, Carin R., Burich, Rebekah A., Zill, Oliver A., Lee, Christine E., Riess, Jonathan W., Mortimer, Stefanie A., Talasaz, AmirAli, Lanman, Richard B., Gandara, David R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7383626/ https://www.ncbi.nlm.nih.gov/pubmed/32365229 http://dx.doi.org/10.1002/cncr.32876 |
Ejemplares similares
-
Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer
por: Villaflor, Victoria, et al.
Publicado: (2016) -
Altitude 8000
por: Murail, Tristan
Publicado: (1975) -
Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay
por: Schwaederle, Maria, et al.
Publicado: (2016) -
Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA
por: Lanman, Richard B., et al.
Publicado: (2015) -
Next‐Generation Sequencing of Circulating Tumor DNA Reveals Frequent Alterations in Advanced Hepatocellular Carcinoma
por: Ikeda, Sadakatsu, et al.
Publicado: (2018)